Nalini R Shastri

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4907528/publications.pdf

Version: 2024-02-01

64 papers	1,718 citations	279487 23 h-index	301761 39 g-index
65 all docs	65 docs citations	65 times ranked	2227 citing authors

#	Article	IF	Citations
1	Enhanced solubility, permeability, and tabletability of nicorandil by salt and cocrystal formation. CrystEngComm, 2021, 23, 227-237.	1.3	37
2	Tuning Diffusion Permeability of an Anti-Retroviral Drug, Emtricitabine, via Multicomponent Crystallizations. Crystal Growth and Design, 2021, 21, 1548-1561.	1.4	12
3	The effects of cis and trans butenedioic acid on the physicochemical behavior of lumefantrine. CrystEngComm, 2021, 24, 156-168.	1.3	4
4	Classification of the crystallization tendency of active pharmaceutical ingredients (APIs) and nutraceuticals based on their nucleation and crystal growth behaviour in solution state. Drug Delivery and Translational Research, 2020, 10, 70-82.	3.0	10
5	Generation and Evaluation of Pharmacologically Relevant Drugâ€“Drug Cocrystal for Gout Therapy. Crystal Growth and Design, 2020, 20, 3577-3583.	1.4	22
6	Amorphous solid dispersion of nisoldipine by solvent evaporation technique: preparation, characterization, in vitro, in vivo evaluation, and scale up feasibility study. Drug Delivery and Translational Research, 2020, 10, 903-918.	3.0	23
7	Preparation and optimization of nano-sized cocrystals using a quality by design approach. CrystEngComm, 2020, 22, 2304-2314.	1.3	19
8	Overview of Multicomponent Solid Forms. , 2020, , 65-102.		0
9	Co amorphous valsartan nifedipine system: Preparation, characterization, in vitro and in vivo evaluation. European Journal of Pharmaceutical Sciences, 2019, 139, 105048.	1.9	26
10	Hepatoprotective Cocrystals of Isoniazid: Synthesis, Solid State Characterization, and Hepatotoxicity Studies. Crystal Growth and Design, 2019, 19, 5161-5172.	1.4	20
11	Mechanochemical synthesis of brexpiprazole cocrystals to improve its pharmaceutical attributes. CrystEngComm, 2019, 21, 800-806.	1.3	18
12	Quantification of niclosamide polymorphic forms â€“ A comparative study by Raman, NIR and MIR using chemometric techniques. Talanta, 2019, 199, 679-688.	2.9	19
13	Formulation and evaluation of cyclodextrin complexes for improved anticancer activity of repurposed drug: Niclosamide. Carbohydrate Polymers, 2019, 212, 252-259.	5.1	55
14	Brexpiprazoleâ€“catechol cocrystal: structure elucidation, excipient compatibility and stability. CrystEngComm, 2019, 21, 6703-6708.	1.3	14
15	Cellulose based polymers in development of amorphous solid dispersions. Asian Journal of Pharmaceutical Sciences, 2019, 14, 248-264.	4.3	76
16	An ab initio molecular dynamics method for cocrystal prediction: validation of the approach. CrystEngComm, 2019, 21, 7233-7248.	1.3	23
17	Role of Valsartan as an Antiplasticizer in Development of Therapeutically Viable Drugâ€“Drug Coamorphous System. Crystal Growth and Design, 2018, 18, 1944-1950.	1.4	20
18	Continuous manufacturing of co-crystals: challenges and prospects. Drug Delivery and Translational Research, 2018, 8, 1726-1739.	3.0	39

#	Article	IF	Citations
19	Hollow crystal generation through polymorphic transformation â€“ a case study of flufenamic acid. CrystEngComm, 2018, 20, 275-279.	1.3	6
20	Hepatoprotective Cocrystals and Salts of Riluzole: Prediction, Synthesis, Solid State Characterization, and Evaluation. Crystal Growth and Design, 2018, 18, 1047-1061.	1.4	36
21	Polymorphic transformation as a result of atovaquone incompatibility with selected excipients. Journal of Thermal Analysis and Calorimetry, 2018, 131, 2129-2139.	2.0	6
22	Rufinamide: Crystal structure elucidation and solid state characterization. Journal of Pharmaceutical and Biomedical Analysis, 2018, 149, 185-192.	1.4	7
23	Overview of Multicomponent Solid Forms. Journal of Nanotoxicology and Nanomedicine, 2018, 3, 23-48.	0.7	2
24	Determination of precipitation inhibitory potential of polymers from amorphous solid dispersions. Drug Development and Industrial Pharmacy, 2018, 44, 1933-1941.	0.9	16
25	Multicomponent Solid Forms. Advances in Medical Technologies and Clinical Practice Book Series, 2018, , 273-300.	0.3	1
26	Generation of Hollow Crystals of a Drug with Lamellar Structure Forming Ability. Crystal Growth and Design, 2017, 17, 1480-1483.	1.4	10
27	Fast dissolving drug-drug eutectics with improved compressibility and synergistic effects. European Journal of Pharmaceutical Sciences, 2017, 104, 82-89.	1.9	39
28	Solid lipid nanoparticles as vesicles for oral delivery of olmesartan medoxomil: formulation, optimization and in vivo evaluation. Drug Development and Industrial Pharmacy, 2017, 43, 611-617.	0.9	28
29	Preparation, characterization, and cytotoxicity studies of niclosamide loaded mesoporous drug delivery systems. International Journal of Pharmaceutics, 2017, 528, 202-214.	2.6	34
30	Inorganic Nanocompositesâ€"A New Paradigm in Drug Delivery. , 2017, , 317-357.		0
31	Nanocrystals for Delivery of Therapeutic Agents. , 2017, , 291-316.		2
32	Lipid Carriers: Role and Applications in Nano Drug Delivery. , 2017, , 253-289.		3
33	Near infra red spectroscopy: a tool for solid state characterization. Drug Discovery Today, 2017, 22, 1835-1843.	3.2	25
34	Spherical Agglomeration of Platy Crystals: Curious Case of Etodolac. Crystal Growth and Design, 2016, 16, 4034-4042.	1.4	30
35	Emu oil based nano-emulgel for topical delivery of curcumin. International Journal of Pharmaceutics, 2016, 506, 222-236.	2.6	80
36	Evaluation of the inhibitory potential of HPMC, PVP and HPC polymers on nucleation and crystal growth. RSC Advances, 2016, 6, 77569-77576.	1.7	63

#	Article	IF	Citations
37	Co amorphous systems: A product development perspective. International Journal of Pharmaceutics, 2016, 515, 403-415.	2.6	139
38	Syringic Acid: Structural Elucidation and Co-Crystallization. Crystal Growth and Design, 2016, 16, 4679-4687.	1.4	32
39	Crystal engineered albendazole with improved dissolution and material attributes. CrystEngComm, 2016, 18, 1489-1494.	1.3	30
40	Design and optimization of disintegrating pellets of MCC by non-aqueous extrusion process using statistical tools. European Journal of Pharmaceutical Sciences, 2016, 84, 146-156.	1.9	12
41	Multidrug co-crystals: towards the development of effective therapeutic hybrids. Drug Discovery Today, 2016, 21, 481-490.	3.2	164
42	Can crystal engineering be as beneficial as micronisation and overcome its pitfalls?: A case study with cilostazol. International Journal of Pharmaceutics, 2015, 491, 26-34.	2.6	21
43	Modulating drug release profiles by lipid semi solid matrix formulations for BCS class II drug â€“ anin vitroand anin vivostudy. Drug Delivery, 2015, 22, 418-426.	2.5	6
44	Effect of HPMC concentration on crystal habit of nifedipine. CrystEngComm, 2015, 17, 1615-1624.	1.3	17
45	Micellar carriers for the delivery of multiple therapeutic agents. Colloids and Surfaces B: Biointerfaces, 2015, 135, 291-308.	2.5	78
46	The role of surface chemistry in crystal morphology and its associated properties. CrystEngComm, 2015, 17, 6646-6650.	1.3	7
47	Effect of surfactant concentration on nifedipine crystal habit and its related pharmaceutical properties. Journal of Crystal Growth, 2015, 422, 44-51.	0.7	17
48	Design of a novel type IV lipid-based delivery system for improved delivery of drugs with low partition coefficient. Journal of Liposome Research, 2015, 25, 325-333.	1.5	9
49	Can vacuum morphologies predict solubility and intrinsic dissolution rate? A case study with felodipine polymorph form IV. Journal of Computational Science, 2015, 10, 178-185.	1.5	5
50	Ionic, Neutral, and Hybrid Acidâ€“Base Crystalline Adducts of Lamotrigine with Improved Pharmaceutical Performance. Crystal Growth and Design, 2015, 15, 5816-5826.	1.4	29
51	Impact of Nisoldipine Crystal Morphology on Its Biopharmaceutical Properties: A Layer Docking Assisted Study. Organic Process Research and Development, 2015, 19, 1912-1917.	1.3	10
52	Semi solid matrix formulations of meloxicam and tenoxicam: an in vitro and in vivo evaluation. Archives of Pharmacal Research, 2015, 38, 801-812.	2.7	11
53	Improved anti-diabetic activity of glibenclamide using oral self nano emulsifying powder. Journal of Microencapsulation, 2015, 32, 54-60.	1.2	23
54	Solid self-nanoemulsifying drug delivery system (S-SNEDDS) for oral delivery of glimepiride: development and antidiabetic activity in albino rabbits. Drug Delivery, 2015, 22, 499-508.	2.5	58

#	Article	IF	Citations
55	Polymerâ€“Drug Conjugate in Focal Drug Delivery. Advances in Delivery Science and Technology, 2014, , 117-147.	0.4	4
56	Designed Isomorphism of Nifedipine: A Joint Experimental and Molecular Simulation Study with Screened Solvents and Antisolvents. Crystal Growth and Design, 2014, 14, 326-338.	1.4	13
57	Impact of surface area of silica particles on dissolution rate and oral bioavailability of poorly water soluble drugs: A case study with aceclofenac. International Journal of Pharmaceutics, 2014, 461, 459-468.	2.6	63
58	Exploration of crystal simulation potential by fluconazole isomorphism and its application in improvement of pharmaceutical properties. Journal of Crystal Growth, 2014, 406, 18-25.	0.7	4
59	Development and validation of RP-HPLC method for glimepiride and its application for a novel self-nanoemulsifying powder (SNEP) formulation analysis and dissolution study. Journal of Analytical Science and Technology, 2014, 5, .	1.0	7
60	A Validated Stability-Indicating RP-HPLC Method for the Simultaneous Determination of Tenofovir, Emtricitabine, and a Efavirenz and Statistical Approach to Determine the Effect of Variables. ISRN Chromatography, 2013, 2013, 1-8.	0.6	16
61	RP-HPLC SEPARATION METHOD FOR INDIVIDUAL COMPONENTS OF POLYCAP IN PRESENCE OF THEIR DEGRADATION/INTERACTION PRODUCTS. Journal of Liquid Chromatography and Related Technologies, 2012, 35, 662-676.	0.5	5
62	Use of the liquisolid compact technique for improvement of the dissolution rate of valsartan. Acta Pharmaceutica Sinica B, 2012, 2, 502-508.	5.7	64
63	HPLC AND LC-MS STUDIES ON STRESS DEGRADATION BEHAVIOR OF LEVOCETIRIZINE AND DEVELOPMENT OF A VALIDATED SPECIFIC STABILITY-INDICATING METHOD. Journal of Liquid Chromatography and Related Technologies, 2011, 34, 955-965.	0.5	2
64	Development of Taste Masked Fast Disintegrating Films of Levocetirizine Dihydrochloride for Oral Use. Current Drug Delivery, 2010, 7, 21-27.	0.8	47